10 nucleic acid detection companies made profits in the first half of the year, with total profits exceeding 654.38+0.6 billion, with the largest increase of nearly 400%.

After the normalization of epidemic prevention and control, it is difficult for most enterprises to make money, but the listed companies that detect nucleic acids are profitable. Recently, ten listed companies for nucleic acid testing released the semi-annual report for 2022. At first glance, it is found that the total revenue of ten listed companies is 485 18 billion yuan, and the total net profit reaches/kloc-0.6297 billion yuan. From the perspective of growth rate, the revenue and net profit of ten listed companies have achieved substantial growth. Jinyu Pharmaceutical has the smallest increase in net profit of 55. 1 1%, Mingde Bio has the fastest growth rate of 376.29%, and Wei Lan Pharmaceutical has exceeded 300%. In terms of branches, Daan Gene is the most profitable, with revenue of 6.676 billion yuan, net profit of 43. 13 and profit rate of 64.6%. In the semi-annual performance report of 2022, the company indicated that the market demand for nucleic acid detection kits, nucleic acid detection instruments and related consumables in novel coronavirus continued, which had a positive impact on the company's performance. The revenue scale of Dean Diagnostics is the largest among the ten. In the first half of the year, the total revenue of the company's diagnostic service business was 6.952 billion yuan, an increase of 154. 10% compared with the same period of last year. Among them, COVID-19's income from nucleic acid testing was 4.748 billion yuan. The company undertook the task of nucleic acid detection in 30 provinces such as Zhejiang, Tianjin, Jiangsu, Inner Mongolia, Heilongjiang, Henan, Shanghai and Beijing, and completed the nucleic acid detection1500,000 tubes in COVID-19. Egg-based organisms have the smallest revenue among the ten companies, but the net profit rate is not low, reaching 33.9%. In the first half of the year, the company developed pet detection products on the molecular diagnosis platform, and completed a series of nucleic acid detection of dog/cat pathogens, including respiratory tract, digestive tract, anemia, zoonosis and so on. Jinyu Medical is a leading listed company in the field of nucleic acid detection. According to Dean's diagnosis, its revenue reached 8310.20 billion yuan, its profit was10.643 billion yuan, and its growth rate was 5.5 1. 1%, which was not high compared with the other nine companies. In the first half of the year, most of Capbio's income came from nucleic acid detection. According to the company's interim report, in the first half of the year, it mainly undertook large-scale COVID-19 screening tasks in Shaanxi, Liaoning, Shanghai, Guangdong, Hong Kong, Yunnan, Inner Mongolia, Beijing Winter Olympics and Hubei. Over 260 million person-times have been inspected in COVID-19, with a revenue of 2.205 billion yuan, up 158.42% year-on-year. Wei Lan Pharmaceutical Co., Ltd. is a Shanghai enterprise. Benefiting from the outbreak of Shanghai epidemic in the first quarter of this year, the company made a lot of money. Both revenue and net profit have achieved substantial growth. However, due to the long payback period of the large-scale screening nucleic acid detection business, the cash flow dropped by 24 13.04%. On August 9 this year, the company said on the interactive platform that the company has built a full-scene nucleic acid detection system of "central laboratory, gas film laboratory and shelter laboratory" to meet the requirements of detection tasks, and continuously improve the detection capability. At present, the level of nucleic acid detection in Shanghai laboratory is not less than 200,000 tubes/day. Mingde Bio has the largest profit growth rate among the ten listed companies, reaching an astonishing 376.29% and a net profit rate of 52.54%. In the interim report, the company said that in the first half of 2022, a serious epidemic broke out in many places in China. In order to prevent the epidemic from spreading on a large scale, the state built a normalized nucleic acid detection system, which prompted COVID-19 to maintain a high demand for nucleic acid detection reagents during the non-epidemic period. In April, 2022, the commonly used nucleic acid reagents and kits were collected by Guangdong 18 provincial alliance. In the first half of the year, the company's COVID-19 nucleic acid detection reagent realized an operating income of 3.042 billion yuan, a year-on-year increase of 270.5438+0%. Mingde Bio is headquartered in Wuhan. In June 2000, an epidemic broke out in Wuhan, and the company began to develop testing products in COVID-19. On March 2, 2020, the company's COVID-19 nucleic acid detection reagent passed the national emergency examination and approval. Up to now, the company's COVID-19 nucleic acid detection reagents have been collected and purchased in more than 30 provinces in China, including Hubei, Xinjiang, Heilongjiang, Guangdong, Guangxi, Hunan and Zhejiang. Ten listed companies have the least net profit, only 0.9 1 billion, but they have also achieved an increase of 243.94%. The company is headquartered in Beijing, and Beijing Puni Medical Laboratory is the first batch of COVID-19 nucleic acid detection institutions announced in Beijing. Up to now, fourteen medical laboratories under the company have been approved to carry out nucleic acid detection business. Wanfu Bio's profits soared because the sales of PCR instruments and nucleic acid extraction instruments doubled. In the first half of the year, Ubos U-Box automatic nucleic acid amplification and analysis system developed by the company was approved. The system can automatically realize all the experimental processes of nucleic acid extraction, amplification and analysis, and can automatically produce results and print reports within 1 hour. Wan Tai Bio's net profit growth rate and net profit rate are very high. In the first half of the year, the operating income was 5.93 billion yuan, up by 2,065,438+0.92% year-on-year; The net profit was 2.69 billion yuan, a year-on-year increase of 273.24%. Earned a lot of money, mainly because the company's bivalent HPV vaccine sales increased, revenue and profits achieved rapid growth. At the same time, affected by the COVID-19 epidemic at home and abroad, the income and profits of the company's COVID-19 raw materials and COVID-19 detection reagents have achieved rapid growth. In the industrial chain related to epidemic prevention and control, there are many companies making money, and the listed companies related to nucleic acid detection are undoubtedly the closest to the money. These companies make money easily, which gives birth to the so-called "epidemic economy".